Business Context and Reporting Period
This Form 8-K Current Report is filed by Relmada Therapeutics, Inc. (formerly Camp Nine, Inc.) for the reporting period ending August 6, 2014. The filing documents the official completion of a corporate name change and the associated updates to trading identifiers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure regarding corporate identity changes and does not contain financial performance data.
Material Changes
- Corporate Name: The Company changed its name from Camp Nine, Inc. to Relmada Therapeutics, Inc., effective August 6, 2014, following approval by the Financial Industry Regulatory Authority (FINRA).
- Trading Symbol: The stock ticker symbol was updated to "RLMD", effective August 6, 2014.
- CUSIP Number: The Company's new CUSIP number is 75955J105.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934. No risks, contingencies, or unusual items are disclosed in this specific document.
Investor Verification Checklist
- Verify the new ticker symbol "RLMD" on trading platforms.
- Confirm the updated CUSIP number 75955J105 for settlement purposes.
- Review the attached press release (Exhibit 99.1) for strategic context regarding the rebranding.
- Check subsequent filings for the first financial report under the new corporate name.